Tel Aviv, Israel – December 2, 2019 – MaxQ AI, the industry-leading medical diagnostic AI company, today announced that the company’s Accipio intracranial hemorrhage (ICH), stroke, and head trauma platform will be integrated into GE Healthcare’s Edison™ Open AI Orchestrator, which is designed to simplify the deployment of AI for imaging workflows. This addition makes GE Healthcare the first to offer a comprehensive CT and PACS MaxQ AI offering.
A key player in GE Healthcare’s Edison ecosystem, the expansion of MaxQ AI’s Accipio-powered solutions through both the latest PACS and CT offerings will increase access to AI augmented tools for radiologists and care providers around the world to enhance the identification and prioritization of patients suffering from stroke, traumatic brain injury, head trauma, and other life-threatening conditions – both at the CT console and through the distributed review of these images in PACS.
“The ability to integrate our Accipio intracranial hemorrhage (ICH) detection software and slice-level annotation through GE Healthcare’s PACS further solidifies and deepens our successful partnership with GE Healthcare,” said Gene Saragnese, CEO of MaxQ AI. “This will also enable hospitals and acute care providers, who are looking to bring the power of our AI-enabled solutions into their emergency rooms, to seamlessly add these new capabilities into the workflow in the Edison Open AI Orchestrator, a platform for quickly and easily integrating AI-based clinical applications in imaging workflows. An exciting new era of AI-powered innovation, combined with the skills of the care provider, make augmented intelligence available to GE Healthcare customers worldwide.”
MaxQ AI’s ACCIPIO® ICH and Stroke Platform is on display this week as part of demonstrations of GE Healthcare’s Edison™ Open AI Orchestrator during the Radiological Society of North America (RSNA) 2019 Annual Meeting in Chicago
MaxQ AI’s revolutionary ACCIPIO® ICH and Stroke Platform integrates into a comprehensive, seamless, and secure workflow to augment acute care teams with deep clinical insight and actionable data in minutes. These AI-powered insights enable physicians across the world to make faster assessments of stroke, traumatic brain injury, and head trauma in any location, at any time. Accipio Ix™ provides automatic identification and prioritization of non-contrast head CT images with suspected ICH. Accipio Ax™ delivers automatic slice-level annotation of suspected ICH. Both Accipio Ix and Accipio Ax are FDA Cleared and CE Approved. The Accipio platform is comprised of Class II and Class III medical devices with significant clinical evidence.
